Stromal-derived factor-1 and inflammatory cytokines in retinal vein occlusion

Current Eye Research

Volumn 32, Issue 12, 2007, Pages 1065-1072

  Ki I, Yuya ^a   Arimura, Noboru ^a   Noda, Yoshihiro ^b   Yamakiri, Keita ^a   Doi, Norihito ^a   Hashiguchi, Teruto ^a   Maruyama, Ikuro ^a   Shimura, Masahiko ^c   Sakamoto, Taiji ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c NTT East Tohoku Hospital   (Japan)

Author keywords

Chemokine; Cytokine; Retinal vein occlusion; Stromal derived factor 1; Vascular endothelial growth factor

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; INTERLEUKIN DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EPIRETINAL MEMBRANE; EYE INFLAMMATION; FEMALE; HUMAN; IRIS DISEASE; MALE; PRIORITY JOURNAL; RETINA VEIN OCCLUSION; VITRECTOMY; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM; MIDDLE AGED; VITREOUS BODY;

AGED; AGED, 80 AND OVER; CHEMOKINE CXCL12; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY; VITREOUS BODY;

EID: 39149084387     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713680701758727     Document Type: Article

References (26)

1. Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol. 1994;117:429-441.
2. Folkman J. Tumor angiogenesis. Adv Cancer Res. 1974;19:331-358.
3. Wiedemann P. Growth factors in retinal diseases: Proliferative vitreoretinopathy, proliferative diabetic retinopathy, and retinal degeneration. Surv Ophthalmol. 1992;36:373-384.
4. Ratajczak MZ, Zuba-Surma E, Kucia M, et al. The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia. 2006;20:1915-1924.
5. Ruiz de Almodovar C, Luttun A, Carmeliet P. An SDF-1 trap for myeloid cells stimulates angiogenesis. Cell. 2006;124:18-21.
6. Yamaguchi J, Kusano KF, Masuo O, et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation. 2003;107:1322-1328.
7. Salvucci O, Yao L, Villalba S, et al. Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. Blood. 2002;99:2703-2711.
8. Grunewald M, Avraham I, Dor Y, et al. VEGF-induced adult neovascularization: Recruitment, retention, and role of accessory cells. Cell. 2006;124:175-189.
9. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004;10:858-864.
10. Brooks HL, Jr, Caballero S, Jr, Newell CK, et al. Vitreous levels of vascular endothelial growth factor and stromal-derived factor1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch Ophthalmol. 2004;122:1801-1807.
11. Butler JM, Guthrie SM, Koc M, et al. SDF-1 is both necessary and sufficient to promote proliferative retinopathy. J Clin Invest. 2005;115:86-93.
12. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
13. Motro B, Itin A, Sachs L, Keshet E. Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci USA. 1990;87:3092-3096.
14. Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science. 1992;258: 1798-1801.
15. Nagasawa T, Hirota S, Tachibana K, et al. Defects of B-cell lymphopoiesis and bone marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 1996;382:635-638.
16. Stumm RK, Rummel J, Junker V, et al. A dual role for the SDF-1/CXCR4 chemokine receptor system in adult brain: Isoform-selective regulation of SDF-1 expression modulates CXCR4-dependent neuronal plasticity and cerebral leukocyte recruitment after focal ischemia. J Neurosci. 2002;22:5865-5878.
17. Gombert M, Dieu-Nosjean MC, Winterberg F, et al. CCL1-CCR8 interactions: An axis mediating the recruitment of T cells and Langerhans-type dendritic cells to sites of atopic skin inflammation. J Immunol. 2005;174:5082-5091.
18. Khan SS, Smith MS, Reda D, et al. Multiplex bead array assays for detection of soluble cytokines: Comparisons of sensitivity and quantitative values among kits from multiple manufacturers. Cytometry. 2004;61:35-39.
19. Tanaka Y, Katoh S, Hori S, et al. Vascular endothelial growth factor in diabetic retinopathy. Lancet. 1997;349:1520.
20. Klok AM, Luyendijk L, Zaal MJ, et al. Elevated serum IL-8 levels are associated with disease activity in idiopathic intermediate uveitis. Br J Ophthalmol. 1998;82:871-874.
21. Funatsu H, Yamashita H, Noma H, et al. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol. 2002;133:70-77.
22. Adamis AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol. 2002;86:363-365.
23. Odemis V, Moepps B, Gierschik P, Engele J. Interleukin-6 and cAMP induce stromal cell-derived factor-1 chemotaxis in astroglia by upregulating CXCR4 cell surface expression. Implications for brain inflammation. J Biol Chem. 2002;277:39801-39808.
24. Meleth AD, Agron E, Chan CC, et al. Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2005;46:4295-4301.
25. Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: Pathophysiological mechanisms and treatment perspectives. Diabetes/metabolism Research and Reviews. 2003;19:442-455.
26. Spranger J, Buhnen J, Jansen V, et al. Systemic levels contribute significantly to increased intraocular IGF-I, IGF-II and IGF-BP3 [correction of IFG-BP3] in proliferative diabetic retinopathy. Horm Metab Res. 2000;32:196-200.